



## **Abstract Notices**

The Editor of the *2020 ASCO Annual Meeting Proceedings* has authorized correction of the following:

### **101**

**Notice of Correction:** “Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.”

The first author should have been listed as Scott Norberg. Christian S. Hinrichs was incorrectly listed as first author in the printed *2020 ASCO Annual Meeting Proceedings* but was moved to the last author position post-publication.

### **1004**

**Notice of Withdrawal:** “A randomized, open-label, phase III trial of pertuzumab retreatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study.”

Abstract 1004 was withdrawn from online publication and presentation in the ASCO 2020 Virtual Scientific Program at the authors’ request due to not being able to confirm the detailed data for the presentation because of strict social and medical restrictions around the COVID-19 outbreak and being unable to access the data centers at each institute.

### **1012**

**Notice of Withdrawal:** “Association of pathologic complete response following pertuzumab and trastuzumab in HER2-positive breast cancer with intrinsic subtype and activation of immune processes (TBCRC026).”

Abstract 1012 was withdrawn from online publication and presentation in the ASCO 2020 Virtual Scientific Program at the authors’ request due to discrepancies in pathologic response (pCR) data that had the potential to affect individual point estimates in the abstract.

### **1045**

**Notice of Withdrawal:** “Interstitial lung disease in Japanese patients with HER2-expressing metastatic breast cancer receiving trastuzumab deruxtecan.”

Abstract 1045 was withdrawn from online publication and presentation in the ASCO 2020 Virtual Scientific Program at the authors’ request as they decided to carry out a larger data analysis to the results.

### 3013

**Notice of Retraction:** “Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).”

ASCO’s Prior Publication Policy requires that the contents and conclusions of the abstract not be published in a scientific, medical, or educational publication (in any medium), in whole or in part, before the ASCO Meeting. Abstract 3013, published in the *2020 ASCO Annual Meeting Proceedings*, violated this policy and was retracted from publication and presentation in the ASCO 2020 Virtual Scientific Program.

### 3025

**Notice of Correction:** “CD56<sup>bright</sup>/CD16<sup>bright</sup> NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R/R) AML.”

Due to a communication error, abstract 3025 was omitted from the printed *2020 ASCO Annual Meeting Proceedings*. ASCO apologizes for the error.

### 3033

**Notice of Correction:** “Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition.”

Due to a press error, abstract 3033 was omitted from the printed *2020 ASCO Annual Meeting Proceedings*. ASCO apologizes for the error.

### 3104

**Notice of Withdrawal:** “Combination therapy with DPX-Survivac, intermittent low-dose cyclophosphamide (CPA) and pembrolizumab for the treatment of advanced and metastatic solid tumors: Early safety and efficacy results from a phase II basket study.”

Abstract 3104 was withdrawn from online publication and presentation in the ASCO 2020 Virtual Scientific Program at the authors’ request. Due to COVID-19 closures, they were unable to collect and analyze the data necessary to complete their poster on time.

### 7012

**Notice of Retraction:** “Association of behavioral nudges with high-value evidence-based prescribing in oncology.”

Abstract 7012 was retracted from publication and will not be presented in the ASCO 2020 Virtual Scientific Program due to a violation of ASCO’s Prior Publication Policy.

### 8010

**Notice of Withdrawal:** “Durable responses to REGN1979, a human CD20 x CD3 bispecific antibody (bsAb), in patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) including with or without (w/wo) prior chimeric antigen receptor T-cell therapy (CAR T).”

Abstract 8010 was withdrawn from online publication and presentation in the ASCO 2020 Virtual Scientific Program at the authors' request due to limited enrollment as a consequence of COVID-19.

**e18109**

**Notice of Correction:** "Impact of inpatient hospitalization on opiate usage for minimally invasive hysterectomy amongst gynecologic oncology patients."

First author Amy Gee was inadvertently left off the abstract in the printed *2020 ASCO Annual Meeting Proceedings*. ASCO apologizes for the error.

*All errors have been corrected in the online versions of the abstracts on JCO.org and ASCO.org. This notice is updated on a rolling basis, as needed.*